Real-World Effectiveness and Safety of Upadacitinib Plus Vedolizumab vs Upadacitinib Monotherapy During Induction in Moderate-to-Severe Ulcerative Colitis

NCT07442045 · clinicaltrials.gov ↗

RECRUITING

Status

150

Enrollment

OTHER

Sponsor class

Conditions

Ulcerative Colitis (UC)

Interventions

DRUG: Upadacitinib
DRUG: Vedolizumab

Sponsor

Sixth Affiliated Hospital, Sun Yat-sen University